"The Reddit discussion highlights concerns regarding the competitive landscape for $FDA, questioning whether larger companies could replicate its products and the implications for its market position. Additionally, there is skepticism about investing in a stock with a negative P/E ratio, with participants weighing the potential for a turnaround against the inherent risks, ultimately debating its classification as a value stock."